|1.||Goldberg, Richard M: 34 articles (04/2015 - 10/2003)|
|2.||André, Thierry: 26 articles (12/2015 - 01/2003)|
|3.||Van Cutsem, Eric: 26 articles (12/2015 - 04/2002)|
|4.||de Gramont, Aimery: 25 articles (12/2015 - 04/2002)|
|5.||Tabernero, Josep: 20 articles (12/2015 - 06/2004)|
|6.||Cheng, Ann-Lii: 19 articles (01/2014 - 02/2002)|
|7.||Shimada, Yasuhiro: 18 articles (09/2015 - 01/2002)|
|8.||Muro, Kei: 18 articles (04/2015 - 01/2002)|
|9.||Rougier, Philippe: 18 articles (03/2015 - 06/2002)|
|10.||de Gramont, A: 18 articles (02/2015 - 08/2000)|
|1.||Colorectal Neoplasms (Colorectal Cancer)
10/01/1991 - "Recent clinical trials have demonstrated that both the response rate and the survival time of patients with advanced colorectal cancer can be significantly improved by the addition of leucovorin (CF) to FUra. "
03/01/1990 - "These results suggest that the efficacy of FUra in patients with advanced, measurable, metastatic colorectal cancer can be enhanced significantly by administration of a continuous high-dose infusion of leucovorin calcium."
10/01/2000 - "However, because knowledge and experience with UFT plus leucovorin are relatively limited in Japan, we conducted a phase II study to evaluate the safety and efficacy of this combination in Japanese patients with metastatic colorectal cancer. "
01/01/2001 - "The application for FDA approval of UFT with leucovorin as a first-line treatment regimen for advanced colorectal cancer is pending. "
06/01/2000 - "Efficacy of UFT plus oral leucovorin in advanced colorectal cancer: a multicenter study."
|2.||Colonic Neoplasms (Colon Cancer)
03/22/2001 - "The mainstay of treatment of colon cancer is 5-Fluoruracil (5-FU), which should be combined with folinic acid in case of bolus (2-4 min. injection) therapy. "
06/01/2014 - "Patients with stage IIB or III colon cancer who had undergone curative resection were randomly assigned to receive UFT (300 mg/m(2)) plus leucovorin (75 mg/day) for 6 months (control group, 4 weeks of treatment followed by a 1-week rest, five courses) or for 18 months (study group, 5 days of treatment followed by a 2-day rest, 15 courses). "
05/01/2009 - "In the present study, we explored the therapeutic potential of combined in vivo treatment in the human colon cancer cell lines COL-1, KM12C and KM20C with consecutive oral S-1 and leucovorin (LV) in 2-week therapeutic periods. "
02/01/2001 - "The International Multicenter Pooled Analysis of Colon Cancer Trials B2 study, which combined data from patients with Dukes' B colon cancer in five separate trials, failed to show a statistically significant benefit of adjuvant 5-FU/leucovorin compared with surgery alone. "
02/01/2001 - "The aim of the IMPACT 2 study was to determine whether 5-FU/leucovorin is an effective adjuvant treatment for patients with Dukes' B2 colon cancer. "
|3.||Stomach Neoplasms (Stomach Cancer)
01/01/2011 - "The aim of this study was to evaluate the efficacy and safety of the modified FOLFOX-4 using low dose leucovorin for patients with advanced gastric cancer and analyze the efficacy of this regimen as first-line and salvage treatment. "
01/01/1996 - "Our results suggest that orally administered low-dose leucovorin can add to the efficacy of UFT in patients with gastric cancer, and provide preliminary data for a randomized clinical trial."
08/01/2005 - "A phase II trial of haptaplatin/5-FU and leucovorin for advanced stomach cancer."
07/01/2009 - "Efficacy and toxicity of lower dose UFT without leucovorin in metastatic gastric cancer patients."
05/01/2007 - "As the tested regimen was generally safe and well tolerated by the patients, MMC plus infusional 5-FU/folinic acid may be a potential second-line regimen for patients with advanced gastric cancer."
07/01/1996 - "CPG2 rescue is a safe, effective alternative to leucovorin rescue after HD MTX and may prove particularly useful for the treatment of MTX-sensitive CNS tumors, as it does not affect CSF MTX levels."
01/01/1997 - "We evaluated the anti-tumor efficacy of the combined modality of UFT with oral l-leucovorin. "
01/01/2001 - "Clinical trials of UFT, with or without leucovorin, demonstrate the safety of this regimen and an efficacy comparable to that of bolus 5-FU/leucovorin in the treatment of gastrointestinal tumors. "
04/01/1989 - "In patients with metastatic disease, serial biopsies of tumor and normal tissues for studies of pharmacodynamic responses to test-dose FUra or folinic acid are shown to be easily added to routine intraoperative management. "
01/01/2015 - "Relative expression of 22 genes putatively involved in leucovorin transport, polyglutamation and metabolism was determined in tumor and mucosa samples using quantitative real-time polymerase chain reaction. "
|5.||Neoplasm Metastasis (Metastasis)
10/01/2000 - "Greater efficacy of UFT plus leucovorin was demonstrated in patients with lung metastases, with a response rate of 63% (five of eight patients). "
02/01/2014 - "We conducted the phase III trial to evaluate UFT/leucovorin (LV) for colorectal liver metastases (CRLM). "
08/15/1997 - "Five of the six metastases that showed trapping belonged to patients who received folinic acid. "
07/01/2008 - "[A patient in whom oral UFT/Leucovorin therapy proved markedly effective for lung metastasis after surgery for colon cancer]."
11/01/2003 - "[A case of multiple hepatic metastases from colorectal cancer effectively treated by arterial infusion therapy with Leucovorin/5-FU]."
|9.||Leucovorin (Folinic Acid)
|1.||Drug Therapy (Chemotherapy)
|2.||Combination Drug Therapy (Combination Chemotherapy)